Related references
Note: Only part of the references are listed.Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2
Xingui Liu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)
Selective degradation-inducing probes for studying cereblon (CRBN) biology
Chelsea E. Powell et al.
RSC MEDICINAL CHEMISTRY (2021)
The role of LRRK2 in cell signalling
Kirsten Harvey et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2019)
LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same
Daniel C. Berwick et al.
MOLECULAR NEURODEGENERATION (2019)
Plasticity in binding confers selectivity in ligand-induced protein degradation
Radoslaw P. Nowak et al.
NATURE CHEMICAL BIOLOGY (2018)
Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer's disease
Cheril Tapia-Rojas et al.
NEURAL REGENERATION RESEARCH (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity
Jack D. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
The genetics and neuropathology of Parkinson's disease
Henry Houlden et al.
ACTA NEUROPATHOLOGICA (2012)
The importance of Wnt signalling for neurodegeneration in Parkinson's disease
Daniel C. Berwick et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2012)
(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD
C-Y Chen et al.
CELL DEATH AND DIFFERENTIATION (2012)
LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6
Daniel C. Berwick et al.
HUMAN MOLECULAR GENETICS (2012)
Role of LRRK2 kinase dysfunction in Parkinson disease
Azad Kumar et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2011)
On the Road to Leucine-Rich Repeat Kinase 2 Signalling: Evidence from Cellular and in vivo Studies
V. Daniels et al.
NEUROSIGNALS (2011)
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization
Nicolas Dzamko et al.
BIOCHEMICAL JOURNAL (2010)
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions
Elisa Greggio et al.
ASN NEURO (2009)
Leucine-Rich Repeat Kinase 2 (LRRK2): A Key Player in the Pathogenesis of Parkinson's Disease
Payal N. Gandhi et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2009)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy et al.
LANCET NEUROLOGY (2008)
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
E. R. Dorsey et al.
NEUROLOGY (2007)
Share Paper
